TD Private Client Wealth LLC Decreases Position in Genmab A/S (NASDAQ:GMAB)

TD Private Client Wealth LLC lessened its position in Genmab A/S (NASDAQ:GMAB) by 14.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,816 shares of the company’s stock after selling 2,038 shares during the period. TD Private Client Wealth LLC’s holdings in Genmab A/S were worth $288,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Legacy Wealth Asset Management LLC raised its holdings in Genmab A/S by 1.1% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock worth $1,097,000 after acquiring an additional 471 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after purchasing an additional 478 shares during the last quarter. Eagle Asset Management Inc. lifted its holdings in shares of Genmab A/S by 10.0% during the third quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock valued at $285,000 after purchasing an additional 1,121 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Genmab A/S by 7.1% during the second quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock valued at $470,000 after purchasing an additional 1,236 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Genmab A/S by 43.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after buying an additional 1,413 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Morgan Stanley restated an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. Redburn Atlantic initiated coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Truist Financial cut their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Wednesday, October 16th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Genmab A/S presently has an average rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Trading Down 2.3 %

GMAB opened at $20.17 on Friday. The firm’s 50 day simple moving average is $22.15 and its two-hundred day simple moving average is $25.07. The company has a market capitalization of $13.35 billion, a PE ratio of 19.58, a PEG ratio of 0.67 and a beta of 0.96. Genmab A/S has a 1-year low of $20.12 and a 1-year high of $32.88.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The company had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same period in the prior year, the business posted $0.47 earnings per share. Equities analysts forecast that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.